WHO Updates HIV Treatment Guidelines with Simplified Regimens and Enhanced Prevention

On the first week of January, the World Health Organization released a set of updated clinical guidelines for HIV treatment that amounts to a significant recalibration of how the disease should be managed globally. The new recommendations, the first major update since 2021, reflect five years of accumulated evidence about what works best—and what works best at scale, in resource-constrained settings where most people living with HIV actually receive care.

The centerpiece is a shift toward simplicity. Dolutegravir-based regimens are now the confirmed first choice for anyone starting HIV treatment or switching regimens. For patients who need a protease inhibitor—typically those whose virus has developed resistance to other drugs—darunavir combined with ritonavir becomes the preferred option, replacing the older standards of atazanavir or lopinavir. The WHO also now endorses reusing tenofovir and abacavir in later treatment lines, a move that sounds technical but carries real weight: it means fewer new drugs needed, lower costs, and better outcomes than previously thought possible.

Beyond pills, the guidelines introduce long-acting injectable antiretroviral therapy for adults and adolescents who struggle with the discipline of daily oral medication. For those whose virus is fully suppressed, two-drug oral regimens are now acceptable alternatives to the traditional three-drug combinations. These are not minor tweaks. They represent a philosophy shift toward meeting people where they are rather than demanding they conform to rigid treatment protocols.

The prevention of mother-to-child transmission remains a persistent challenge despite decades of progress. New infant infections still occur, particularly when mothers breastfeed. The updated guidance takes a person-centered approach: mothers with HIV are encouraged to breastfeed exclusively for the first six months, continuing to 12 months or longer if they choose, provided their own viral load is suppressed through antiretroviral therapy. All infants exposed to HIV in utero or during birth should receive six weeks of preventive medication after birth, ideally nevirapine, with higher-risk infants receiving a three-drug combination. Extended prophylaxis can continue until the mother's virus is undetectable or breastfeeding stops. The framework acknowledges both the nutritional and immunological benefits of breastfeeding while protecting the infant through medication and maternal viral suppression.

Tuberculosis remains the leading cause of death among people living with HIV, a fact that has not changed despite all other advances. To address this, WHO now recommends a three-month course of weekly isoniazid plus rifapentine—abbreviated as 3HP—as the preferred preventive regimen for adults and adolescents with HIV. This is shorter and simpler than previous options, which matters enormously for completion rates and adherence. When patients actually finish their TB prevention course, TB deaths decline. The shorter timeline also means services can be better integrated, reducing the burden on already-stretched health systems.

Dr. Tereza Kasaeva, who directs HIV, TB, and viral hepatitis efforts at WHO headquarters in Geneva, framed the update as a commitment to practical medicine. Simplifying treatment regimens, she noted, improves adherence. Addressing gaps in prevention saves lives. The recommendations are designed to be implemented by national HIV programs, clinicians, and community health workers in countries where the vast majority of people living with HIV receive their care.

These guidelines will be woven into WHO's next consolidated HIV treatment manual and distributed globally. They represent not a revolution in HIV science—the drugs themselves are not new—but a recalibration of how to deploy existing tools most effectively across health systems that range from well-resourced to severely constrained. The emphasis throughout is on what actually works in practice, not just in clinical trials.